Novartis Korea Attains New Indication for Diovan

Published: 2005-04-01 06:59:00

Updated: 2005-04-01 06:59:00

Novartis Korea announced that it has received an approval by the Korea Food and Drug Administration (KFDA) on the additional indication for Diovan (active ingredient: valsartan) as a first-line, post MI (myocardial infarction) treatment in high-risk patients.

Diovan, a highly selective angiote...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK